China Medicine Corporation, a distributor and developer of ethical and over-the-counter drugs, traditional Chinese medicines, nutritional and dietary supplements, medical devices, and medical formulations in China says it has been selected by the Guangzhou Technology Bureau to represent Guangzhou city's biotechnology industry at the 15th Annual BIO International Convention, hosted by the Biotechnology Industry Organization. The convention will be held from June 17th to June 20th 2008 at San Diego Convention Center in San Diego, California.
China Medicine Corporation will present the development of its proprietary drugs -- Yutian Capsule, a class II TCM new drug, together with KY Polysaccharides and Aflatoxin Detoxifyzyme at BIO.
Yutian Capsule and KY Polysaccharide have been developed for the treatment of lung disease and lung cancer. Both these products have been approved by the Guangzhou Technology Bureau. China Medicine has successfully shown the chemical structure as well as the molecular weight of the compounds in these two drugs. This is a breakthrough for Traditional Chinese Medicine research as TCM has entered a new era of molecular level research.
In addition, China Medicine will also present its Aflatoxin-Detoxifizyme (ADTZ) project, which has been accepted by the High-Tech National Natural Science Foundation of China as a part of the China's National "863 Plan." ADTZ is an enzyme that can eliminate aflatoxin from food and animal feed.
"This is an important event for China Medicine as we will be representing the entire biotechnology industry in Guangzhou city to participate in this conference. Guangzhou Technology bureau intends to leverage this conference as an opportunity to showcase and globalize the city's biotechnology development," said Mr. Senshan Yang, Chairman and CEO of China Medicine.